Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Nutrition Journal
|
March 22, 2013
Maternal dietary intake of nitrates, nitrites and nitrosamines and selected birth defects in offspring: a case-control study
John C Huber, Jean D Brender, Qi Zheng, et al.
Pharmacoepidemiology and Drug Safety
|
September 18, 2024
Exposure to Valsartan Products Containing Nitrosamine Impurities in the United States, Canada, and Denmark
Efe Eworuke, Mayura U Shinde, Laura Hou, et al.
Pharmacoepidemiology and Drug Safety
|
April 2, 2024
Validity of inpatient electronic health record-based measures of oxygen-related therapy in the United States: Lessons applicable for studying COVID-19 endpoints
Candace C Fuller, Edward Rosen, Ashish Rai, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology
|
May 30, 2013
Prenatal exposure to nitrosatable drugs, vitamin C, and risk of selected birth defects
Mayura U Shinde, Ann M Vuong, Jean D Brender, et al.
American Journal of Epidemiology
|
March 9, 2016
Prenatal Exposure to Nitrosatable Drugs, Dietary Intake of Nitrites, and Preterm Birth
Ann M Vuong, Mayura U Shinde, Jean D Brender, et al.
American Journal of Epidemiology
|
November 4, 2011
Nitrosatable drug exposure during early pregnancy and neural tube defects in offspring: National Birth Defects Prevention Study
Jean D Brender, Martha M Werler, Katherine E Kelley, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology
|
August 21, 2012
Nitrosatable drug exposure during the first trimester of pregnancy and selected congenital malformations
Jean D Brender, Martha M Werler, Mayura U Shinde, et al.
Paediatric and Perinatal Epidemiology
|
December 11, 2014
Nitrosatable Drug Exposure during Pregnancy and Preterm and Small-for-Gestational-Age Births
Ann M Vuong, Mayura U Shinde, Jean D Brender, et al.
Pharmacoepidemiology and Drug Safety
|
April 14, 2026
Identifying COVID-19 Disease Severity in Real-World Data: Implications for Medical Product Effectiveness Studies
Mayura U Shinde, Katherine Shapiro, Laura Hou, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 11, 2022
Discovery of MDV6058 (PF-06952229), a selective and potent TGFβR1 inhibitor: Design, synthesis and optimization
Brahmam Pujala, Sreekanth A Ramachandran, Mukesh Sonawane, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Nutrition Journal
|
March 22, 2013
Maternal dietary intake of nitrates, nitrites and nitrosamines and selected birth defects in offspring: a case-control study
John C Huber, Jean D Brender, Qi Zheng, et al.
Pharmacoepidemiology and Drug Safety
|
September 18, 2024
Exposure to Valsartan Products Containing Nitrosamine Impurities in the United States, Canada, and Denmark
Efe Eworuke, Mayura U Shinde, Laura Hou, et al.
Pharmacoepidemiology and Drug Safety
|
April 2, 2024
Validity of inpatient electronic health record-based measures of oxygen-related therapy in the United States: Lessons applicable for studying COVID-19 endpoints
Candace C Fuller, Edward Rosen, Ashish Rai, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology
|
May 30, 2013
Prenatal exposure to nitrosatable drugs, vitamin C, and risk of selected birth defects
Mayura U Shinde, Ann M Vuong, Jean D Brender, et al.
American Journal of Epidemiology
|
March 9, 2016
Prenatal Exposure to Nitrosatable Drugs, Dietary Intake of Nitrites, and Preterm Birth
Ann M Vuong, Mayura U Shinde, Jean D Brender, et al.
American Journal of Epidemiology
|
November 4, 2011
Nitrosatable drug exposure during early pregnancy and neural tube defects in offspring: National Birth Defects Prevention Study
Jean D Brender, Martha M Werler, Katherine E Kelley, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology
|
August 21, 2012
Nitrosatable drug exposure during the first trimester of pregnancy and selected congenital malformations
Jean D Brender, Martha M Werler, Mayura U Shinde, et al.
Paediatric and Perinatal Epidemiology
|
December 11, 2014
Nitrosatable Drug Exposure during Pregnancy and Preterm and Small-for-Gestational-Age Births
Ann M Vuong, Mayura U Shinde, Jean D Brender, et al.
Pharmacoepidemiology and Drug Safety
|
April 14, 2026
Identifying COVID-19 Disease Severity in Real-World Data: Implications for Medical Product Effectiveness Studies
Mayura U Shinde, Katherine Shapiro, Laura Hou, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 11, 2022
Discovery of MDV6058 (PF-06952229), a selective and potent TGFβR1 inhibitor: Design, synthesis and optimization
Brahmam Pujala, Sreekanth A Ramachandran, Mukesh Sonawane, et al.
Page
of 5